Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Gili Kenet,1,2 Thomas Moulton,3 Brian M Wicklund,4 Sanjay P Ahuja,5 Miguel Escobar,6 Johnny Mahlangu7 1National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel; 2The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel; 3Bayer, Whippany, NJ, USA; 4Children’...

Full description

Bibliographic Details
Main Authors: Kenet G, Moulton T, Wicklund BM, Ahuja SP, Escobar M, Mahlangu J
Format: Article
Language:English
Published: Dove Medical Press 2023-06-01
Series:Journal of Blood Medicine
Subjects:
fviii
hemophilia a
prophylaxis
recombinant proteins
octocog alfa
Online Access:https://www.dovepress.com/switching-from-sucrose-formulated-rfviii-to-octocog-alfa-bay-81-8973-p-peer-reviewed-fulltext-article-JBM

Internet

https://www.dovepress.com/switching-from-sucrose-formulated-rfviii-to-octocog-alfa-bay-81-8973-p-peer-reviewed-fulltext-article-JBM

Similar Items